Pharming Group (PHGUF) to Release Quarterly Earnings on Thursday

Pharming Group (OTCMKTS:PHGUF) is projected to issue its resultson Thursday, July 30th. Analysts expect Pharming Group to post earnings of $0.0063 per share and revenue of $101.2830 million for the quarter.

Pharming Group (OTCMKTS:PHGUF) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.01) earnings per share for the quarter. Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The firm had revenue of $72.45 million during the quarter, compared to the consensus estimate of $92.06 million.

Pharming Group Price Performance

OTCMKTS:PHGUF opened at $1.30 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.63 and a quick ratio of 2.06. Pharming Group has a 1-year low of $1.14 and a 1-year high of $2.17. The company has a 50-day moving average of $1.24 and a 200 day moving average of $1.52. The firm has a market cap of $872.39 million, a PE ratio of 65.03 and a beta of 0.47.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.